The endocannabinoid system and Post Traumatic Stress Disorder (PTSD): From preclinical findings to innovative therapeutic approaches in clinical settings - PubMed

Review

The endocannabinoid system and Post Traumatic Stress Disorder (PTSD): From preclinical findings to innovative therapeutic approaches in clinical settings

Andrea Berardi et al. Pharmacol Res. 2016 Sep.

Abstract

Post-Traumatic Stress Disorder (PTSD) is a psychiatric chronic disease developing in individuals after the experience of an intense and life-threatening traumatic event. The post-traumatic symptomatology encompasses alterations in memory processes, mood, anxiety and arousal. There is now consensus in considering the disease as an aberrant adaptation to traumatic stress. Pharmacological research, aimed at the discovery of new potential effective treatments, has lately directed its attention towards the "so-called" cognitive enhancers. This class of substances, by modulating cognitive processes involved in the development and/or persistence of the post-traumatic symptomatology, could be of great help in improving the outcome of psychotherapies and patients' prognosis. In this perspective, drugs acting on the endocannabinoid system are receiving great attention due to their dual ability to modulate memory processes on one hand, and to reduce anxiety and depression on the other. The purpose of the present review is to offer a thorough overview of both animal and human studies investigating the effects of cannabinoids on memory processes. First, we will briefly describe the characteristics of the endocannabinoid system and the most commonly used animal models of learning and memory. Then, studies investigating cannabinoid modulatory influences on memory consolidation, retrieval and extinction will be separately presented, and the potential benefits associated with each approach will be discussed. In the final section, we will review literature data reporting beneficial effects of cannabinoid drugs in PTSD patients.

Keywords: 2-arachidonoylglicerol; Anandamide; Endocannabinoid system; FAAH; JZL184; MAGL; Memory consolidation; Memory extinction; Memory of emotionally arousing experiences; Memory retrieval; Traumatic stress disorder; URB597; WIN55,212-2.

Similar articles

• Cannabinoids and post-traumatic stress disorder: clinical and preclinical evidence for treatment and prevention.

  Mizrachi Zer-Aviv T, Segev A, Akirav I. Mizrachi Zer-Aviv T, et al. Behav Pharmacol. 2016 Oct;27(7):561-9. doi: 10.1097/FBP.0000000000000253. Behav Pharmacol. 2016. PMID: 27551883 Review.

• Enhancing Endocannabinoid Neurotransmission Augments The Efficacy of Extinction Training and Ameliorates Traumatic Stress-Induced Behavioral Alterations in Rats.

  Morena M, Berardi A, Colucci P, Palmery M, Trezza V, Hill MN, Campolongo P. Morena M, et al. Neuropsychopharmacology. 2018 May;43(6):1284-1296. doi: 10.1038/npp.2017.305. Epub 2017 Dec 21. Neuropsychopharmacology. 2018. PMID: 29265107 Free PMC article.

• Targeting the endocannabinoid system to treat anxiety-related disorders.

  Korem N, Zer-Aviv TM, Ganon-Elazar E, Abush H, Akirav I. Korem N, et al. J Basic Clin Physiol Pharmacol. 2016 May 1;27(3):193-202. doi: 10.1515/jbcpp-2015-0058. J Basic Clin Physiol Pharmacol. 2016. PMID: 26426887 Review.

• The effects of enhancing endocannabinoid signaling and blocking corticotrophin releasing factor receptor in the amygdala and hippocampus on the consolidation of a stressful event.

  Aisenberg N, Serova L, Sabban EL, Akirav I. Aisenberg N, et al. Eur Neuropsychopharmacol. 2017 Sep;27(9):913-927. doi: 10.1016/j.euroneuro.2017.06.006. Epub 2017 Jun 26. Eur Neuropsychopharmacol. 2017. PMID: 28663121

• The Endocannabinoid System Modulating Levels of Consciousness, Emotions and Likely Dream Contents.

  Murillo-Rodriguez E, Pastrana-Trejo JC, Salas-Crisóstomo M, de-la-Cruz M. Murillo-Rodriguez E, et al. CNS Neurol Disord Drug Targets. 2017;16(4):370-379. doi: 10.2174/1871527316666170223161908. CNS Neurol Disord Drug Targets. 2017. PMID: 28240187 Review.

Cited by

• Cannabidiol as a Therapeutic Alternative for Post-traumatic Stress Disorder: From Bench Research to Confirmation in Human Trials.

  Bitencourt RM, Takahashi RN. Bitencourt RM, et al. Front Neurosci. 2018 Jul 24;12:502. doi: 10.3389/fnins.2018.00502. eCollection 2018. Front Neurosci. 2018. PMID: 30087591 Free PMC article. Review.

• Polypharmacological Approaches for CNS Diseases: Focus on Endocannabinoid Degradation Inhibition.

  Papa A, Pasquini S, Contri C, Gemma S, Campiani G, Butini S, Varani K, Vincenzi F. Papa A, et al. Cells. 2022 Jan 29;11(3):471. doi: 10.3390/cells11030471. Cells. 2022. PMID: 35159280 Free PMC article. Review.

• Elevated fatty acid amide hydrolase in the prefrontal cortex of borderline personality disorder: a [¹¹C]CURB positron emission tomography study.

  Kolla NJ, Mizrahi R, Karas K, Wang C, Bagby RM, McMain S, Simpson AI, Rusjan PM, Tyndale R, Houle S, Boileau I. Kolla NJ, et al. Neuropsychopharmacology. 2020 Oct;45(11):1834-1841. doi: 10.1038/s41386-020-0731-y. Epub 2020 Jun 10. Neuropsychopharmacology. 2020. PMID: 32521537 Free PMC article.

• Meet Your Stress Management Professionals: The Endocannabinoids.

  deRoon-Cassini TA, Stollenwerk TM, Beatka M, Hillard CJ. deRoon-Cassini TA, et al. Trends Mol Med. 2020 Oct;26(10):953-968. doi: 10.1016/j.molmed.2020.07.002. Epub 2020 Aug 28. Trends Mol Med. 2020. PMID: 32868170 Free PMC article. Review.

• Use of Medicinal Cannabis and Synthetic Cannabinoids in Post-Traumatic Stress Disorder (PTSD): A Systematic Review.

  Orsolini L, Chiappini S, Volpe U, Berardis D, Latini R, Papanti GD, Corkery AJM. Orsolini L, et al. Medicina (Kaunas). 2019 Aug 23;55(9):525. doi: 10.3390/medicina55090525. Medicina (Kaunas). 2019. PMID: 31450833 Free PMC article.

Publication types

MeSH terms

Substances

LinkOut - more resources

• Full Text Sources

  • Elsevier Science
  • Ovid Technologies, Inc.

• Other Literature Sources

  • scite Smart Citations

• Medical

  • MedlinePlus Health Information